MONTREAL, Sept. 06, 2018 (GLOBE NEWSWIRE) — Pediapharm, Inc. (“Pediapharm”) (TSXV: PDP, OTCQX: PDDPF) is pleased to announce that it has entered into definitive agreements to acquire two speciality pharmaceutical companies and also intends to complete a private placement offering for up to CDN$60 million.

Pediapharm logo

PEDIAPHARM is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community.

Medexus logo

MEDEXUS is a Canadian specialty pharmaceutical company focused on the licensing, registration, marketing, sales and distribution of innovative pharmaceutical products in Canada.

Medexus Pharm logo

MEDEXUS PHARMA is a specialty pharmaceutical company focusing on the development and commercialization of treatments for autoimmune diseases and oncology in the United States.


What's New

October 15, 2019
Medexus Announces Changes to Senior Management
Read More >

September 19, 2019
Medexus Reports Annual Meeting Results
Read More >

September 12, 2019
Medexus Reports Health Quality Ontario Recommends Gliolan® for Public Reimbursement
Read More >


Medexus Pharmaceuticals Inc., D, TSXV